Seeking Alpha
02 Jun 2026, 08:23 UTC · 2h ago
Bristol Myers' Growth Portfolio Just Overtook The Legacy One
Search tags
Seeking Alpha
02 Jun 2026, 08:23 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
Bristol Myers Squibb's DCF valuation suggests a share price of $68.5, representing a roughly 20% upside from current levels. — A direct claim of significant undervaluation based on fundamental analysis typically drives buying interest.
+0.60The company has four near-term pipeline catalysts—iberdomide, mezigdomide, milvexian, and Cobenfy—expected within seven months. — Clinical or regulatory catalysts are primary drivers of volatility and price re-ratings for biotech/pharma stocks.
+0.50BMY's Growth Portfolio revenues surpassed its Legacy revenues in Q1 2026. — Evidence that new products are successfully offsetting patent cliffs reduces the 'melting ice cube' risk profile.
+0.40Ticker attribution
Model heads
Continue reading
6 related stories
The author argues the stock is undervalued with strong pipeline catalysts and a projected 20% upside.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 10 offered
Invezz
2h ago
